Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | FOS | P01100 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616760 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL20788033 | 0.90 | ALDH1A1 (0.60) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL20788032 | 0.90 | ALDH1A1 (0.60) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL5135534 | 0.89 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL5135532 | 0.89 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL14508502 | 0.85 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2PKMNPSR1 | |
| SCHEMBL6792463 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2BCHEMAOB | |
| SCHEMBL20788019 | 0.83 | ALDH1A1 (0.52) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL20788020 | 0.83 | ALDH1A1 (0.52) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 | |
| SCHEMBL3614708 | 0.82 | THRB (0.58) | KDM4EALDH1A1SMN1; SMN2PKMAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | KDM4E 1835/4885ALDH1A1 3196/4885SMN1; SMN2 2253/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | KDM4E 1803/4885ALDH1A1 3103/4885SMN1; SMN2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.